Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabotegravir + rilpivirine long-acting every 8 weeks versus every 4 weeks in virologically suppressed adults with HIV-1
2017-002946-62Phase 3Active
- Sponsor
- ViiV Healthcare
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion of participants with plasma HIV-1 RNA greater than or equal to 50 copies/mL. Started Sep 2017; status: active.
02
Drugs
cabotegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2017-002946-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002946-62.